Mary Reumuth compensation by year
KALA BIO Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $468,000 | $438,962 |
| Bonus | $147,420 | $475,550 |
| Stock awards | $32,200 | $76,053 |
| Option awards | $120,021 | $285,040 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $10,627 | $47,002 |
| Total | $778,269 | $1,322,608 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: KALA BIO, Inc. DEF 14A filed September 24, 2026, accession 0001829126-26-010384, and prior-year filings. Open the filing on EDGAR.
How this page was built: the KALA BIO, Inc. filed document, accession 0001829126-26-010384. Every figure is read from that document and cited to the page and table it appears in. Filed September 24, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 12,051 | $6,700 | — |
| RSU | 10,100 | $5,616 | — |
| RSU | 3,176 | $1,766 | — |
| RSU | 3,067 | $1,705 | — |
| RSU | 512 | $285 | — |
| Option | 10,677 | — | $7.00 |
| Option | 34,842 | — | $7.53 |
| Option | 18,072 | — | $14.56 |
Per the Outstanding Equity Awards at Fiscal Year-End table in KALA BIO, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
KALA BIO’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Todd Bazemore | Former Interim Chief Executive Officer, President and Chief Operating Officer | $3,476,972 |
| Kim Brazzell | Former Head of Research and Development and Chief Medical Officer | $1,358,174 |
| Mary Reumuth · this page | Former Chief Financial Officer | $1,322,608 |
| Mark Iwicki | Former Chief Executive Officer | $906,642 |
The full KALA BIO compensation record
free company briefThis page is one person within KALA BIO's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are KALA BIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.